Obeticholic acid (OCA) is an effective FXR agonist and is widely applied in chronic liver disease studies such as non-alcoholic fatty liver disease (NAFLD) and primary biliary cholangitis (PBC) [39]. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.